A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies

Trisha Wise-Draper,Ganesh Moorthy,Mohamad Adham Salkeni,Nagla Abdel Karim,Hala Elnakat Thomas,Carol A. Mercer,M. Shalaan Beg,Sue O’Gara,Olugbenga Olowokure,Hassana Fathallah,Sara C. Kozma,George Thomas,Olivier Rixe,Pankaj B. Desai,John C. Morris

A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies

2017

Trisha Wise-Draper
Ganesh Moorthy
Mohamad Adham Salkeni
Nagla Abdel Karim
Hala Elnakat Thomas
Carol A. Mercer
M. Shalaan Beg
Sue O’Gara
Olugbenga Olowokure
Hassana Fathallah
Sara C. Kozma
George Thomas
Olivier Rixe
Pankaj B. Desai
John C. Morris

Background The combination of everolimus and the imidazoquinoline derivative, BEZ235 (dactolisib), a dual PI3K/mTOR inhibitor, demonstrated synergy in a preclinical model.

Keywords:

Immunology
Subependymal giant cell astrocytoma
PI3K/AKT/mTOR pathway
Pharmacology
Imidazoquinoline
Discovery and development of mTOR inhibitors
Medicine
Tumor lysis syndrome
Everolimus
in patient
Drug synergism

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations